Restless legs syndrome: Pathophysiology, clinical presentation and management

Nature Reviews Neurology

Volumn 6, Issue 6, 2010, Pages 337-346

  Trenkwalder, Claudia ^a   Paulus, Walter ^b  

^a Paracelsus Elena Hospital   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; DEXTROPROPOXYPHENE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRIC HYDROXIDE SUCROSE; FERRITIN; GABAPENTIN; GABAPENTIN ENACARBIL; IRON; IRON DEXTRAN; LEVODOPA; MAGNESIUM; OPIATE AGONIST; OXYCODONE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ABDOMINAL PAIN; APPLICATION SITE REACTION; BEDTIME DOSAGE; BLOOD PRESSURE; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DAYTIME SOMNOLENCE; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EVENING DOSAGE; FERRITIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; HEADACHE; HUMAN; IRON DEFICIENCY; IRON THERAPY; LABORATORY TEST; LOW DRUG DOSE; NAUSEA; NEUROTRANSMISSION; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PERIODIC LIMB MOVEMENT DISORDER; PHYSICAL EXAMINATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANALGESICS, OPIOID; ANIMALS; ANTICONVULSANTS; BRAIN; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRITINS; HUMANS; IRON; RESTLESS LEGS SYNDROME; SYNAPTIC TRANSMISSION;

EID: 77954855475     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.55     Document Type: Review

References (162)

1. Trenkwalder, C. & Paulus, W. Why do restless legs occur at rest-pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin. Neurophysiol. 115, 1975-1988 (2004).
2. Allen, R. P. et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 4, 101-119 (2003).
3. Walters, A. S. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov. Disord. 10, 634-642 (1995).
4. Hening, W. & Trenkwalder, C. Restless legs syndrome. In Movement Disorders (eds Schapira, A. et al.) 587-621 (Saunders Elsevier, Philadelphia, 2009).
5. Winkelmann, J. et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann. Neurol. 52, 297-302 (2002).
6. Allen, R. P. & Earley, C. J. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med. 1, 11-19 (2000).
7. Benes, H. & Kohnen, R. validation of an algorithm for the diagnosis of Restless Legs Syndrome: the Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med. 10, 515-523 (2009).
8. Benes, H., Von Eye, A. & Kohnen, R. Empirical evaluation of the accuracy of diagnostic criteria for Restless Legs Syndrome. Sleep Med. 10, 524-530 (2009).
9. Okura, K. et al. Comparison of sleep variables between chronic widespread musculoskeletal pain, insomnia, periodic leg movements syndrome and control subjects in a clinical sleep medicine practice. Sleep Med. 9, 352-361 (2008).
10. Hening, W., Allen, R., Washburn, M., Leasage, S. & Earley, C. Mimics of the restless legs syndrome can often satisfy the standard diagnostic criteria [abstract]. Sleep 27, A297 (2004).
11. Benes, H., Walters, A. S., Allen, R. P., Hening, W. A. & Kohnen, R. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov. Disord. 22 (Suppl. 18), S401-S408 (2007).
12. Stiasny-Kolster, K., Kohnen, R., Möller, J. C., Trenkwalder, C. & Oertel, W. H. validation of the "l-DOPA test" for diagnosis of restless legs syndrome. Mov. Disord. 21, 1333-1339 (2006).
13. Montplaisir, J. et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov. Disord. 13, 324-329 (1998).
14. Brodeur, C., Montplaisir, J., Godbout, R. & Marinier, R. Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: a double-blind, controlled study. Neurology 38, 1845-1848 (1988).
15. Michaud, M., Lavigne, G., Desautels, A., Poirier, G. & Montplaisir, J. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov. Disord. 17, 112-115 (2002).
16. Michaud, M., Paquet, J., Lavigne, G., Desautels, A. & Montplaisir, J. Sleep laboratory diagnosis of restless legs syndrome. Eur. Neurol. 48, 108-113 (2002).
17. Aksu, M., Demirci, S. & Bara-Jimenez, W. Correlation between putative indicators of primary restless legs syndrome severity. Sleep Med. 8, 84-89 (2007).
18. Michaud, M. et al. Circadian variation of the effects of immobility on symptoms of restless legs syndrome. Sleep 28, 843-846 (2005).
19. Birinyi, P. v., Allen, R. P., Lesage, S., Dean, T. & Earley, C. J. Investigation into the correlation between sensation and leg movement in restless legs syndrome. Mov. Disord. 20, 1097-1103 (2005).
20. Hening, W. A. et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 22, 901-912 (1999).
21. Trenkwalder, C. et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov. Disord. 14, 102-110 (1999).
22. Michaud, M. et al. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann. Neurol. 55, 372-380 (2004).
23. García-Borreguero, D. et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov. Disord. 22 (Suppl. 18), S476-S484 (2007).
24. Montplaisir, J. et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov. Disord. 12, 61-65 (1997).
25. Hening, W. et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 5, 237-246 (2004).
26. Hornyak, M., Feige, B., voderholzer, U., Philipsen, A. & Riemann, D. Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study. Sleep 30, 861-865 (2007).
27. Allen, R. P. & Earley, C. J. validation of the Johns Hopkins restless legs severity scale. Sleep Med. 2, 239-242 (2001).
28. García-Borreguero, D., Larrosa, O., De La Llave, Y., Granizo, J. J. & Allen, R. Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. Sleep Med. 5, 561-565 (2004).
29. Hornyak, M. et al. Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients. Clin. Neurophysiol. 118, 1532-1537 (2007).
30. Trenkwalder, C. et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 62, 1391-1397 (2004). (Pubitemid 38526054)
31. Allen, R. et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27, 907-914 (2004).
32. Hornyak, M., Feige, B., Riemann, D. & voderholzer, U. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. Sleep Med. Rev. 10, 169-177 (2006).
33. Bliwise, D. L., Petta, D., Seidel, W. & Dement, W. Periodic leg movements during sleep in the elderly. Arch. Gerontol. Geriatr. 4, 273-281 (1985).
34. Ancoli-Israel, S. et al. Periodic limb movements in sleep in community-dwelling elderly. Sleep 14, 496-500 (1991).
35. Coleman, R. M. Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In Sleeping and Waking Disorders: Indications and Techniques (ed. Guilleminault, C.) 265-295 (Addison-Wesley Pub. Co., Medical/ Nursing Division, Menlo Park, CA, 1982).
36. Ferri, R., Gschliesser, v., Frauscher, B., Poewe, W. & Högl, B. Periodic leg movements during sleep and periodic limb movement disorder in patients presenting with unexplained insomnia. Clin. Neurophysiol. 120, 257-263 (2009).
37. Zucconi, M. et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med. 7, 175-183 (2006).
38. Boehm, G., Wetter, T. C. & Trenkwalder, C. Periodic leg movements in RLS patients as compared to controls: Are there differences beyond the PLM index? Sleep Med. 10, 566-571 (2009).
39. Ferri, R. et al. Computer-assisted detection of nocturnal leg motor activity in patients with restless legs syndrome and periodic leg movements during sleep. Sleep 28, 998-1004 (2005).
40. Kushida, C. A. et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 28, 499-521 (2005).
41. Hornyak, M. et al. Consensus statement from the German Sleep Society: indications for performing polysomnography in the diagnosis and treatment of restless leg syndrome. Sleep Med. 3, 457-458 (2002).
42. Gschliesser, V. et al. PLM detection by actigraphy compared to polysomnography: a validation and comparison of two actigraphs. Sleep Med. 10, 306-311 (2009).
43. Stefansson, H. et al. A genetic risk factor for periodic limb movements in sleep. N. Engl. J. Med. 357, 639-647 (2007).
44. Allen, R. P. Improving RLS diagnosis and severity assessment: polysomnography, actigraphy and RLS-sleep log. Sleep Med. 8 (Suppl. 2), S13-S18 (2007).
45. Hening, W. A., Allen, R. P., Washburn, M., Lesage, S. & Earley, C. J. validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Med. 9, 283-289 (2008).
46. Walters, A. S. et al. validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 4, 121-132 (2003).
47. Abetz, L. et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med. 7, 340-349 (2006).
48. Atkinson, M. J. et al. validation of the Restless Legs Syndrome Quality of Life Instrument (RLSQLI): findings of a consortium of national experts and the RLS Foundation. Qual. Life Res. 13, 679-693 (2004).
49. Kell, D. B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2, 2 (2009).
50. Paulus, W. & Schomburg, E. D. Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation? Sleep Med. Rev. 10, 185-196 (2006).
51. Clemens, S., Rye, D. & Hochman, S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67, 125-130 (2006).
52. Heckman, C. J., Mottram, C., Quinlan, K., Theiss, R. & Schuster, J. Motoneuron excitability: the importance of neuromodulatory inputs. Clin. Neurophysiol. 120, 2040-2054 (2009).
53. Monte-Silva, K. et al. Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans. J. Neurosci. 29, 6124-6131 (2009).
54. Nitsche, M. A. et al. Serotonin affects transcranial direct current-induced neuroplasticity in humans. Biol. Psychiatry 66, 503-508 (2009).
55. Rizzo, V. et al. Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome. Mov. Disord. 24, 710-715 (2009).
56. Paulus, W. & Trenkwalder, C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol. 5, 878-886 (2006).
57. Zhao, H. et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J. Neurosci. Res. 85, 1065-1076 (2007).
58. Paalzow, G. H. l-dopa induces opposing effects on pain in intact rats: (-)-sulpiride, SCH 23390 or alpha-methyl-DL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses. J. Pharmacol. Exp. Ther. 263, 470-479 (1992).
59. Shimizu, T., Iwata, S., Miyata, A., Fukuda, T. & Nomoto, M. Delayed l-DOPA-induced hyperalgesia. Pharmacol. Biochem. Behav. 85, 643-647 (2006).
60. McNab, F. et al. Changes in cortical dopamine D1 receptor binding associated with cognitive training. Science 323, 800-802 (2009).
61. Pappas, S. S., Behrouz, B., Janis, K. L., Goudreau, J. L. & Lookingland, K. J. Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice. Brain Res. 1214, 1-10 (2008).
62. Trenkwalder, C., Högl, B. & Winkelmann, J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J. Neurol. 256, 539-553 (2009).
63. Winkelmann, J. et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat. Genet. 39, 1000-1006 (2007).
64. Schormair, B. et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat. Genet. 40, 946-948 (2008).
65. Bucher, S. F., Seelos, K. C., Oertel, W. H., Reiser, M. & Trenkwalder, C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann. Neurol. 41, 639-645 (1997).
66. Unrath, A., Juengling, F. D., Schork, M. & Kassubek, J. Cortical grey matter alterations in idiopathic restless legs syndrome: An optimized voxel-based morphometry study. Mov. Disord. 22, 1751-1756 (2007).
67. Unrath, A., Muller, H. P., Ludolph, A. C., Riecker, A. & Kassubek, J. Cerebral white matter alterations in idiopathic restless legs syndrome, as measured by diffusion tensor imaging. Mov. Disord. 23, 1250-1255 (2008).
68. Etgen, T. et al. Bilateral thalamic gray matter changes in patients with restless legs syndrome. Neuroimage 24, 1242-1247 (2005).
69. Celle, S. et al. Lack of specific gray matter alterations in restless legs syndrome in elderly subjects. J. Neurol. 257, 344-348 (2010).
70. Hornyak, M. et al. voxel-based morphometry in unmedicated patients with restless legs syndrome. Sleep Med. 9, 22-26 (2007).
71. Cervenka, S. et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 129, 2017-2028 (2006).
72. Turjanski, N., Lees, A. J. & Brooks, D. J. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52, 932-937 (1999).
73. Connor, J. R. et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 132, 2403-2412 (2009).
74. Tergau, F., Wischer, S. & Paulus, W. Motor system excitability in patients with restless legs syndrome. Neurology 52, 1060-1063 (1999).
75. Gorsler, A. & Liepert, J. Influence of cabergoline on motor excitability in patients with restless legs syndrome. J. Clin. Neurophysiol. 24, 456-460 (2007).
76. Nardone, R. et al. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurol. Scand. 114, 244-249 (2006).
77. Von Spiczak, S. et al. The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain 128, 906-917 (2005).
78. Earley, C. J. et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54, 1698-1700 (2000).
79. Clardy, S. L., Earley, C. J., Allen, R. P., Beard, J. L. & Connor, J. R. Ferritin subunits in CSF are decreased in restless legs syndrome. J. Lab. Clin. Med. 147, 67-73 (2006).
80. Earley, C. J., Hyland, K. & Allen, R. P. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med. 7, 263-268 (2006).
81. Astrakas, L. G. et al. T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome. Neurology 71, 911-916 (2008).
82. Allen, R. P. & Earley, C. J. The role of iron in restless legs syndrome. Mov. Disord. 22 (Suppl. 18), S440-S448 (2007).
83. Connor, J. R. Pathophysiology of restless legs syndrome: evidence for iron involvement. Curr. Neurol. Neurosci. Rep. 8, 162-166 (2008).
84. Allen, R. P., Barker, P. B., Wehrl, F., Song, H. K. & Earley, C. J. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56, 263-265 (2001).
85. Earley, C. J., Barker, B. P., Horská, A. & Allen, R. P. MRI-determined regional brain iron concentrations in early-and late-onset restless legs syndrome. Sleep Med. 7, 458-461 (2006).
86. Schmidauer, C. et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann. Neurol. 58, 630-634 (2005).
87. Godau, J., Schweitzer, K. J., Liepelt, I., Gerloff, C. & Berg, D. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov. Disord. 22, 187-192 (2007).
88. Berg, D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. Neurochem. Res. 32, 1646-1654 (2007).
89. Qu, S. et al. Locomotion is increased in A11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J. Neuropathol. Exp. Neurol. 66, 383-388 (2007).
90. Dowling, P., Klinker, F., Amaya, F., Paulus, W. & Liebetanz, D. Iron-deficiency sensitizes mice to acute pain stimuli and formalin-induced nociception. J. Nutr. 139, 2087-2092 (2009).
91. Ondo, W. G., He, Y., Rajasekaran, S. & Le, W. D. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov. Disord. 15, 154-158 (2000).
92. Qu, S. et al. Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp. Brain Res. 168, 152-156 (2006).
93. Schöls, L., Haan, J., Riess, O., Amoiridis, G. & Przuntek, H. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 51, 1603-1607 (1998).
94. Bara-Jimenez, W., Aksu, M., Graham, B., Sato, S. & Hallett, M. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 54, 1609-1616 (2000).
95. Rijsman, R. M., Stam, C. J. & De Weerd, A. W. Abnormal H-reflexes in periodic limb movement disorder; impact on understanding the pathophysiology of the disorder. Clin. Neurophysiol. 116, 204-210 (2005).
96. Stiasny-Kolster, K., Magerl, W., Oertel, W. H., Möller, J. C. & Treede, R. D. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 127, 773-782 (2004).
97. Schattschneider, J. et al. Idiopathic restless legs syndrome: Abnormalities in central somatosensory processing. J. Neurol. 251, 977-982 (2004).
98. Bachmann, C. G. et al. Thermal hypoesthesia differentiates secondary RLS associated with small fibre neuropathy from primary RLS. Brain (in press).
99. Hornyak, M. et al. Cognitive behavioural group therapy to improve patients' strategies for coping with restless legs syndrome: a proof-of-concept trial. J. Neurol. Neurosurg. Psychiatry 79, 823-825 (2008).
100. Fulda, S. & Wetter, T. C. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 131, 902-917 (2008).
101. Trenkwalder, C. et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov. Disord. 23, 2267-2302 (2008).
102. O'Keeffe, S. T., Gavin, K. & Lavan, J. N. Iron status and restless legs syndrome in the elderly. Age Ageing 23, 200-203 (1994).
103. Trenkwalder, C., Högl, B., Benes, H. & Kohnen, R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 9, 572-574 (2008).
104. Trenkwalder, C. et al. l-dopa therapy of uremic and idiopathic restless legs syndrome: a doubleblind, crossover trial. Sleep 18, 681-688 (1995).
105. Walker, S. L., Fine, A. & Kryger, M. H. 1-DOPA/ carbidopa for nocturnal movement disorders in uremia. Sleep 19, 214-218 (1996).
106. Staedt, J. et al. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double -blind randomized crosover trial of pergolide versus l-dopa. J. Neural Transm. 104, 461-468 (1997).
107. Collado-Seidel, V. et al. A controlled study of additional sr-l-dopa in l-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 52, 285-290 (1999).
108. Benes, H. et al. Rapid onset of action of levodopa in restless legs syndrome: a doubleblind, randomized, multicenter, crossover trial. Sleep 22, 1073-1081 (1999).
109. Eisensehr, I., Ehrenberg, B. L., Rogge Solti, S. & Noachtar, S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/ benserazid. J. Neurol. 251, 579-583 (2004).
110. Trenkwalder, C. et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. Mov. Disord. 22, 696-703 (2007).
111. Allen, R. P. & Earley, C. J. Augmentation of the restless legs syndrome with carbidopa/ levodopa. Sleep 19, 205-213 (1996).
112. Trenkwalder, C. et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov. Disord. 18, 1184-1189 (2003).
113. Partinen, M. et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study. Sleep Med. 7, 407-417 (2006).
114. Oertel, W. H. et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 67, 1040-1046 (2006).
115. Adler, C. H. et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 62, 1405-1407 (2004).
116. Trenkwalder, C. et al. Ropinirole in the treatment of restless legs syndrome: results from a 12-week, randomised, placebo-controlled study in 10 European countries. J. Neurol. Neurosurg. Psychiatry 75, 92-97 (2004).
117. Walters, A. S. et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov. Disord. 19, 1414-1423 (2004).
118. Bliwise, D. L. et al. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med. 6, 141-147 (2005).
119. Bogan, R. K., Fry, J. M., Schmidt, M. H., Carson, S. W. & Ritchie, S. Y. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin. Proc. 81, 17-27 (2006).
120. Happe, S., Sauter, C., Klösch, G., Saletu, B. & Zeitlhofer, J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 48, 82-86 (2003).
121. Hansen, R. A. et al. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy 29, 255-262 (2009).
122. Montplaisir, J., Karrasch, J., Haan, J. & volc, D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov. Disord. 21, 1627-1635 (2006).
123. Garcia-Borreguero, D. et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 8, 742-752 (2007).
124. Montplaisir, J., Nicolas, A., Denesle, R. & Gomez-Mancilla, B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52, 938-943 (1999).
125. Winkelman, J. W. et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67, 1034-1039 (2006).
126. Trenkwalder, C. et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov. Disord. 21, 1404-1410 (2006).
127. Oertel, W. H. et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov. Disord. 22, 213-219 (2007).
128. Ferini-Strambi, L. et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, doubleblind, placebo-controlled trial. Sleep Med. 9, 874-881 (2008).
129. Stiasny-Kolster, K., Kohnen, R., Schollmayer, E., Möller, J. C. & Oertel, W. H. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. 19, 1432-1438 (2004).
130. Trenkwalder, C. et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebocontrolled trial. Lancet Neurol. 7, 595-604 (2008).
131. Oertel, W. H. et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebocontrolled, six-week dose-finding trial in Europe. Sleep Med. 9, 228-239 (2008).
132. García-Borreguero, D. et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 8, 520-530 (2007).
133. Earley, C. J. & Allen, R. P. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 7, 592-593 (2006).
134. vetrugno, R. et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov. Disord. 22, 424-427 (2007).
135. Högl, B., Garcia-Borreguero, D., Sohr, M. & Brenner, S. Similar incidences of augmentation during 26 weeks of double-blind pramipexole treatment for restless legs syndrome in comparison to placebo. Neurology 72 (Suppl. 3), A106 (2009).
136. Guilleminault, C., Cetel, M. & Philip, P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 43, 445 (1993).
137. Walters, A. S. et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 16, 327-332 (1993).
138. Kaplan, P. W., Allen, R. P., Buchholz, D. W. & Walters, J. K. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 16, 717-723 (1993).
139. Walters, A. S. et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov. Disord. 16, 1105-1109 (2001).
140. Sommer, M. et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol. Scand. 115, 347-350 (2007).
141. Garcia-Borreguero, D. et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59, 1573-1579 (2002).
142. Thorp, M. L., Morris, C. D. & Bagby, S. P. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am. J. Kidney Dis. 38, 104-108 (2001).
143. Kushida, C. A., Becker, P. M., Ellenbogen, A. L., Canafax, D. M. & Barrett, R. W. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 72, 439-446 (2009).
144. Walters, A. S. et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin. Neuropharmacol. 32, 311-320 (2009).
145. Bermejo, P. E. Restless legs syndrome induced by topiramate: two more cases. J. Neurol. 256, 662-663 (2009).
146. Montagna, P., Sassoli De Bianchi, L., Zucconi, M., Cirignotta, F. & Lugaresi, E. Clonazepam and vibration in restless leg syndrome. Acta Neurol. Scand. 69, 428-430 (1984).
147. Saletu, M. et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur. Neuropsychopharmacol. 11, 153-161 (2001).
148. Peled, R. & Lavie, P. Double-blind evaluation of clonazepam on periodic leg movements in sleep. J. Neurol. Neurosurg. Psychiatry 50, 1679-1681 (1987).
149. Horiguchi, J., Inami, Y., Sasaki, A., Nishimatsu, O. & Sukegawa, T. Periodic leg movements in sleep with restless legs syndrome: effect of clonazepam treatment. Jpn J. Psychiatry Neurol. 46, 727-732 (1992).
150. Bonnet, M. H. & Arand, D. L. The use of triazolam in older patients with periodic leg movements, fragmented sleep, and daytime sleepiness. J. Gerontol. 45, M139-M144 (1990).
151. Bezerra, M. L. & Martínez, J. V. Zolpidem in restless legs syndrome. Eur. Neurol. 48, 180-181 (2002).
152. Davis, B. J., Rajput, A., Rajput, M. L., Aul, E. A. & Eichhorn, G. R. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur. Neurol. 43, 70-75 (2000).
153. Sloand, J. A., Shelly, M. A., Feigin, A., Bernstein, P. & Monk, R. D. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am. J. Kidney Dis. 43, 663-670 (2004).
154. Earley, C. J., Heckler, D. & Allen, R. P. Repeated Iv doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med. 6, 301-305 (2005).
155. Grote, L., Leissner, L., Hedner, J. & Ulfberg, J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov. Disord. 24, 1445-1452 (2009).
156. Wagner, M. L. et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 19, 52-58 (1996).
157. Evidente, V. G., Adler, C. H., Caviness, J. N., Hentz, J. G. & Gwinn-Hardy, K. Amantadine is beneficial in restless legs syndrome. Mov. Disord. 15, 324-327 (2000).
158. Hornyak, M., voderholzer, U., Hohagen, F., Berger, M. & Riemann, D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep 21, 501-505 (1998).
159. Kohnen, R., Oertel, W. H., Stiasny-Kolster, K., Benes, H. & Trenkwalder, C. Severity rating of restless legs syndrome: Review of ten years of experience with the RLS-6 scales in clinical trials [abstract]. Sleep 26, A342 (2003).
160. Kohnen, R., Benes, H., Heinrich, C. R. & Kurella, B. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLSQoL) questionnaire [abstract]. Mov. Disord. 17, A232 (2002).
161. Ware, J. E. Jr & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473-483 (1992).
162. Högl, B., Leissner, L. & Poewe, W. Clinical global impression-improvement (CGI-I) and patient global improvement (PGI) are equivalent and useful tools in measuring treatment effects in restless legs syndrome (RLS) patients [abstract]. Eur. J. Neurol. 12, 215 (2005).